
Fasting earlier or later in day ‘effective strategy for long-term weight loss'
Fasting earlier or later in the day for three months could be an effective strategy for long-term weight loss, research suggests.
Experts found that overweight or obese people who restricted eating to an eight hour 'window' per day shed pounds and managed to keep it off.
The new research, which has not yet been published in a peer-reviewed journal, was presented at the European Congress on Obesity in Malaga.
Lead author Dr Alba Camacho-Cardenosa, from the University of Granada in Spain, said: 'Our study found that restricting the eating window to eight hours at any time of the day for three months can result in significant weight loss for at least a year.
'These benefits can be attributed to the 16-hour fasting window rather than the time of eating.'
A previous randomised controlled trial by the same researchers published in the journal Nature Medicine found that restricting eating to eight hours per day decreased body weight and improved cardiometabolic health.
This kind of intermittent fasting appears feasible for adults with overweight or obesity who wish to have a relatively simple way of losing and maintaining weight loss
Their latest study looked at the long-term effects over 12 months for 99 people.
Individuals were split into four groups for 12 weeks – eating in a 12-hour or more window; restricting eating to an eight-hour window starting before 10am; restricting eating to an eight-hour window starting after 1pm; and allowing people to select their own eight-hour window.
All groups were given tips on a Mediterranean diet to help them eat healthier.
The researchers measured body weight, waist and hip circumferences at the start of the trial, after the 12-week plan, and 12 months later.
The study found that, while those eating over 12 hours or longer lost an average of 1.4kg, the time-restricted groups lost more, at around 3kg to 4kg.
Time-restricted groups also had greater reductions in waist and hip circumferences of several centimetres, and had maintained greater weight loss after 12 months.
At the one-year mark, those eating for 12 hours or more had an average body weight increase of 0.4kg, compared with around a 2kg weight loss in the early and late time restricted groups, the study concluded.
Those who chose their own pattern also maintained some weight loss although this was not statistically significant.
Around 85% to 88% of people restricting their eating window also found they stuck to the plan.
Dr Jonatan Ruiz, study co-ordinator from the University of Granada, said: 'This kind of intermittent fasting appears feasible for adults with overweight or obesity who wish to have a relatively simple way of losing and maintaining weight loss that is less tedious and more time efficient compared with daily calorie counting, but it warrants further investigations in larger and longer-term studies.'
Dr Maria Chondronikola, principal investigator and lead for human nutrition at University of Cambridge Metabolic Research Laboratories, said further studies were needed.
'Understanding how well participants adhered to the timing of their meals, the level of their caloric intake and whether time-restricted eating changed any obesity-related metabolic outcomes would provide valuable insight into the true effectiveness of time-restricted eating,' she said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Extra.ie
21-05-2025
- Extra.ie
Wine not? Spanish researchers looking for volunteers to drink wine every day
There could be a dream job for many in the pipeline in sunny Spain, with one company remaining on the lookout for people to drink wine daily. The University of Navarra Alumni Trialist Initiative (UNATI) in the Basque region of Spain is running a large-scale trial investigating the effects of moderate alcohol consumption. Participants will be part of new research aimed at determining whether drinking a glass of wine a day is actually good for your health, as the adage goes. A new research project is aiming to confirm or disprove whether one glass of wine a day is good for the health. Pic: Getty Images The UNATI trial is the world's largest clinical trial investigating the effects of alcohol in moderation. As part of the project, researchers will track 10,000 people aged 50 to 75 to measure the impact of daily wine, beer, or spirits on rates of heart disease, cancer, mental health disorders, and overall mortality. To date, 6,500 people have joined the study, leaving room for a further 3,500 to get involved. To be eligible, participants must reside in Spain, be men aged 50-70 or women aged 55-75 and habitually consume three alcoholic drinks a week already. A Spanish university is looking for participants for research on moderate alcohol consumption. Pic: Getty Images Within the framework of the project, a person is assigned to one of two groups: one will receive guidance promoting complete abstinence from alcohol, while the other will be encouraged to follow a Mediterranean-style drinking pattern, mainly fermented drinks such as wine or beer. The study is being led by Professor Miguel Angel Martinez-Gonzalez, Chair of Preventive Medicine at the university. He said: 'We currently have 6,500 participants enrolled. We are making good progress in recruiting new volunteers day by day. Please help us, because UNATI means health for all.'


Irish Examiner
20-05-2025
- Irish Examiner
Weight-loss jab Mounjaro helps people shed much more weight than rival
Weight-loss jab Mounjaro – dubbed the 'King Kong' of similar medicines – helps people shed significantly more weight than rival Wegovy, new research suggests. Key research pitching the drugs against each other found Mounjaro was superior when it came to shedding pounds and losing inches, though both drugs worked. Experts presented their findings at the European Congress on Obesity in Malaga and published them in the New England Journal of Medicine. Both Mounjaro (tirzepatide) and Wegovy (semaglutide) are weight-loss medicines that make people feel fuller for longer and therefore less hungry. The new randomised controlled trial involved 751 adult with obesity, but without type 2 diabetes. They received either Mounjaro at the maximum tolerated dose (10mg or 15mg) or Wegovy (1.7mg or 2.4mg) once a week for 72 weeks. The typical age of the people was 45 and most (65%) were female, with a typical body mass index (BMI) of 39. All had at least one known obesity-related complication, such as high blood pressure, sleep apnoea or heart disease. The typical drop in body weight at the end of the trial was a 20.2% reduction with Mounjaro and 13.7% with Wegovy, showing Mounjaro was superior. The drop in waist circumference was also 18.4cm on average with Mounjaro and 13cm with Wegovy. People on Mounjaro were more likely to reach their weight loss goals. One limitation to the study was that people knew which drug they were taking, though the researchers said the findings were in line with previous studies. The research was sponsored by Eli Lilly and Company, the manufacturer of Mounjaro. Our study shows that treatment with tirzepatide was superior to semaglutide with respect to reduction in body weight and waist circumference Dr Louis Aronne, from Weill Cornell Medicine in New York, who led the work, said the dual action of Mounjaro may explain the findings. Both Mounjaro and Wegovy mimic a hormone produced in the body called GLP-1 – a substance that is released in the gut when people consume food. This hormone slows the rate at which food is emptied from the stomach, reduces appetite via the brain and works on insulin levels. But Mounjaro also mimics another hormone known as GIP (glucose-dependent insulinotropic polypeptide). Dr Aronne said: 'Our study shows that treatment with tirzepatide was superior to semaglutide with respect to reduction in body weight and waist circumference. 'Tirzepatide, while a single molecule, pharmacologically activates two metabolic receptors, GIP and GLP-1, which have both overlapping and non-overlapping expression and function. 'This dual agonism of tirzepatide may contribute to the higher weight reduction observed in the current study compared to semaglutide, a mono-agonist.' As people lost weight in the study, health factors such as blood pressure and unhealthy blood fats all improved. Speaking at the European Congress on Obesity in Malaga, Spain on Sunday, Dr Aronne said: 'This is actually the first head-to-head trial of two obesity medications, so I think we're going to start seeing more of these as new medications become available. 'I saw a list the other day of 150 medications… that are now in development, so many people now realise how important it is to manage body weight in addition to other metabolic factors. 'I've called it the golden age of obesity treatment. It took a long time!' Dr Aronne said semaglutide still remained an 'extremely effective' weight loss medication and that the trial did not intended to minimise its effects. He added: 'For example, if you have a patient with a BMI of 32, which is class one obesity, they could get to a BMI in the mid 20s, right around 25 (with semaglutide), which is normal. 'So the majority of people with obesity will do just fine on semaglutide. People at the higher end – class two, class three obesity – may ultimately do better with tirzepatide.'


Irish Independent
16-05-2025
- Irish Independent
Scientists create a chocolate biscuit that helps you lose weight
That's according to an early study that added a new ingredient to confectionery in an attempt to make people feel less hungry. The team from the University of Eastern Piedmont in Italy presented their preliminary findings at the European Congress on Obesity in Malaga, Spain. Researchers said they added a bitter compound from the Artemisia absinthium plant, also known as wormwood, to an ordinary dark chocolate biscuit. A test on 11 healthy people revealed the bitter ingredient made participants feel fuller. Participants were given two different formulas, one cocoa biscuit and the another which had an enriched bitter flavour using 16pc Artemisia absinthium extract. Food cravings were then measured using a questionnaire on how full they felt after eating. Researchers found those who ate the special biscuits felt less hungry and saw an increase in satiety hormones in comparison to those who ate the plain cocoa biscuit. The bitter taste in the added compound regulates how the body releases the hunger hormone ghrelin and GLP-1, a hormone that also regulates blood sugar, appetite and digestion, study authors explained. It is also the same hormone targeted with weight-loss jabs such as Wegovy and diabetes treatments like Ozempic. This hormone reduces food cravings and slows down how quickly food is digested. ADVERTISEMENT This can reduce the rate glucose is absorbed into the bloodstream. As a result, it makes those who take it feel fuller for longer, eat less and lose weight. Study author Dr Flavia Prodam explained that all the people who ate the bitter biscuit reported lower hunger levels before dinner, but not at any other time of the day. The biscuits, which have been described as being 'very tasty', could be sold commercially to help people lose weight, according to Dr Prodam. The team now plans to launch a clinical trial to investigate how the biscuit affects food intake in obese patients. Dr Prodam said: 'This is an important thing to target because we need to educate people to eat less but there is a lot of failure. The emotional part of eating is important in obesity. 'People want comfort foods, so having one that decreases hunger could be a good strategy.'